|By PR Newswire||
|August 29, 2014 06:59 PM EDT||
DUBLIN, Ireland, August 29, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/jjj5vs/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering.
A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer.
The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
07. Market Landscape
08. Pipeline Portfolio
09. Market Segmentation by Class of Drugs
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
- AstraZeneca plc
- Eisai Co. Ltd.
- Daewoong Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Daiichi Sankyo
- Dr. Reddy's Laboratories
- Ferring Pharmaceuticals
- Horizon Pharma
- Johnson and Johnson
- Merck Sharp and Dohme
- Otsuka Holdings
- Rottapharm Madaus
- Taiho Pharmaceutical
- Zeria Pharmaceutical and Zuventus Healthcare
For more information visit http://www.researchandmarkets.com/research/jjj5vs/global_peptic
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 28, 2016 06:30 AM EDT Reads: 1,179
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Oct. 28, 2016 06:30 AM EDT Reads: 1,043
Oct. 28, 2016 06:15 AM EDT Reads: 1,302
Oct. 28, 2016 06:00 AM EDT Reads: 2,193
Oct. 28, 2016 05:45 AM EDT Reads: 606
Oct. 28, 2016 05:00 AM EDT Reads: 3,199
Oct. 28, 2016 04:45 AM EDT Reads: 710
Oct. 28, 2016 04:30 AM EDT Reads: 1,981
Oct. 28, 2016 04:15 AM EDT Reads: 4,145
Oct. 28, 2016 04:15 AM EDT Reads: 678
Oct. 28, 2016 04:15 AM EDT Reads: 1,554
Oct. 28, 2016 04:15 AM EDT Reads: 1,152
Oct. 28, 2016 02:45 AM EDT Reads: 1,788
Oct. 28, 2016 02:30 AM EDT Reads: 1,186
Oct. 28, 2016 02:00 AM EDT Reads: 4,396